Following encouraging research data , retatrutide, a novel peptide therapy for managing non-insulin dependent hyperglycemia , has secured official approval from the Healthcare and Regulatory Agency ( MHRA body). Early availability is currently projected via specialist obesity programs and particular National Health Service organisations in late 202